Related Experiment Video
Updated: Sep 8, 2025
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
Structurally Dynamic Polyplexes Enhance Sentinel Lymph Node Delivery of Antisense Oligonucleotides to Inhibit Breast
Chun Yin Jerry Lau1, Hiroaki Kinoh2, Xueying Liu2
1Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Journal of the American Chemical Society
|June 20, 2025
Summary
This study engineered a dynamic polyplex for targeted delivery of antisense oligonucleotides (ASOs) to sentinel lymph nodes, rejuvenating CD8+ T cells and reducing breast cancer recurrence and metastasis.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
- Drug Delivery
Background:
- Sentinel lymph nodes (SLNs) are critical in tumor progression, and CD8+ T cells within them are often suppressed in advanced cancer.
- Rejuvenating these T cells can potentially slow cancer progression, offering a therapeutic target for breast cancer recurrence and metastasis.
Purpose of the Study:
- To develop a molecular approach for enhancing the functional delivery of antisense oligonucleotides (ASOs) to SLNs.
- To engineer a dynamic polyplex system for targeted delivery and improved gene silencing in SLNs.
- To investigate the potential of this system in rejuvenating CD8+ T cells and reducing breast cancer relapse and metastasis.
Main Methods:
- Engineered a dynamic polyplex using poly(ethylene glycol)-(glycine-lysine)10 [PEG-(GK)10] and antisense oligonucleotides (ASOs).
- Tuned polyplex size by varying PEG size (3-80 kDa) to optimize SLN distribution and limit off-target organ distribution in a murine breast cancer model.
- Utilized conserved glycine-lysine repeats for improved polyplex dynamics and target gene silencing efficiency.
Main Results:
- Achieved enriched ASO distribution in SLNs with minimal off-target organ distribution.
- Demonstrated improved structural dynamics and enhanced target gene silencing efficiency in SLNs using the engineered polyplex.
- Successfully depleted transforming growth factor-β1 (TGF-β1) levels in SLNs, leading to rejuvenated CD8+ T cells, reduced tumor relapse, and decreased lung metastasis.
Conclusions:
- Developed a novel dynamic polyplex for effective ASO delivery to SLNs, enhancing anti-tumor immunity.
- This approach successfully rejuvenated CD8+ T cells by targeting TGF-β1 in SLNs, offering a promising strategy for managing advanced breast cancer.
- The findings provide a molecular rationale for a robust TGF-β1 ASO therapeutic regimen to combat breast cancer recurrence and metastasis.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K